

Critical Response: “Does the Mutation of Cancer Driver Genes *IDH1/2* and CD204 Influence Cancer Metabolism and Tumor Associated Macrophage Recruitment in Tumor Microenvironment” [Letter]

Novaria Sari Dewi Panjaitan , Sarwo Handayani, Rita Marleta Dewi

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, West Java, Indonesia

Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor Km. 46, Bogor, West Java, Indonesia, Email nova014@brin.go.id

Dear editor

We have reviewed and appreciated the work performed by Kurdi et al regarding the mutation in cancer driver genes *IDH1/2* and CD204 and the correlation between mutations found in those genes and the alterations of tumor-associated macrophage recruitment in tumor microenvironment.¹ The IDH gene encodes a NADP(+)-dependent isocitrate dehydrogenase enzyme, which could be found in the cytoplasm and peroxisomes. Based on previous studies, IDH is an essential enzyme involved in major metabolic processes such as the TCA cycle, glutamine metabolism, adipogenesis, and redox regulation.² *IDH1/2* genes were included and reported to be useful as single gene biomarkers used in glioma prognostication.³ In their work, the correlation between *IDH1/2* gene mutations and the expression of CD204 in tumor-associated macrophage (TAM) was evaluated. There was no correlation found between these two factors in the tumor microenvironment, according to their results. However, the result taken from the very small sample size (n=20) used in this study was tricky to state the correlation between factors in a very complicated condition of tumor microenvironment.⁴ Beside the small sample size, the number of patients diagnosed with WHO-grade 4 astrocytoma detected carrying IDH mutations was much lower than those carrying IDH wild-type. Therefore, further research in the same issue with bigger sample size with more patients carrying the IDH mutations are recommended to be performed to take a more responsible conclusion.

Regardless of their small sample size, we appreciated the well performed immunohistochemistry experiment resulting clear definition of high and low expression of CD204 in tumor-associated macrophages. The procedure of this immunohistochemistry was performed following previously designed protocol which explained its sustainability.⁵ Therefore, the conclusion taken regarding the CD204 high expression and tumor early recurrence was pretty clear to be understood. Since the characterization of the tumor (immune) microenvironment has been recognized as an important challenge in this field, the work related to *IDH1/2* mutations in gliomas and immune response profiles was recommended to be unraveled.⁶

Acknowledgments

Appreciation should be given for Kurdi et al for their teamwork in this field. In addition, all authors would like to acknowledge Dr Sunarno and all researchers in Center for Biomedical Research BRIN for the continuous support.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Kurdi M, Mulla N, Katib Y, et al. The cancer driver genes IDH1 and IDH2 and CD204 in WHO-grade 4 astrocytoma: crosstalk between cancer metabolism and tumour associated macrophage recruitment in tumour microenvironment. *Biol Targets Ther.* 2023;17(February):15–22. doi:10.2147/BTT.S394556
2. Roh J, Im M, Kang JH, Youn BH, Kim W. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. *Animal Cells Syst.* 2023;27(1):19–28. doi:10.1080/19768354.2023.2175497
3. Chan AKY, Shi ZF, Li KKW, et al. Combinations of single-gene biomarkers can precisely stratify 1028 adult gliomas for prognostication. *Front Oncol.* 2022;12(April):1–9. doi:10.3389/fonc.2022.839302
4. Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Kristensen BW. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. *Neuropathol Appl Neurobiol.* 2018;44(2):185–206. doi:10.1111/nan.12428
5. Kurdi M, Katib Y, Faizo E, et al. Association between CD204-expressed tumor-associated macrophages and MGMT-promoter methylation in the microenvironment of grade 4 astrocytomas. *World J Oncol.* 2022;13(3):117–125. doi:10.14740/wjon1473
6. Cejalvo T, Gargini R, Segura-Collar B, et al. Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype. *Cancers.* 2020;12(11):1–18. doi:10.3390/cancers12113230

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Biologics: Targets and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Biologics: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Biologics: Targets and Therapy

Dovepress

Publish your work in this journal

Biologics: Targets and Therapy is an international, peer-reviewed journal focusing on the patho-physiological rationale for and clinical application of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/biologics-targets-and-therapy-journal>

<https://doi.org/10.2147/BTT.S410506>